In the Federal Register, FDA has invited public comments to a discussion of issues related to the adoption of continuous manufacturing by the pharmaceutical industry of solid dosage drug products. FDA is particularly interested in public comments about the science, technology, and practices discussed in an Engineering Research Center for Structured Organic Particulate Systems (C-SOPS) document and is opening the docket for that purpose. The comment period closes September 21, 2017. [For more on continuous manufacturing, and on C-SOPS role in particular, see IPQ’s Monthly Updates for February/March and April/May 2017.]
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
